- Open Access
Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients
Journal for ImmunoTherapy of Cancer volume 7, Article number: 9 (2019)
Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:101
Following publication of the original article , the authors reported an error in their listed affiliations.
In this Correction Dr. Jiaxin Zhao is related to two affiliations:
1. The Second Affiliated Hospital & Yuying Children’s Hospital, Wenzhou Medical University, Wenzhou, China.
3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
The published apologizes for any inconvenience caused by this error.
Zhao, et al. Journal for ImmunoTherapy of Cancer. 2018;6(101). https://doi.org/10.1186/s40425-018-0421-z.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Zhao, B., Zhao, H. & Zhao, J. Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients. j. immunotherapy cancer 7, 9 (2019). https://doi.org/10.1186/s40425-018-0487-7